Grifols (ES:GRF) has released an update.
Grifols, a global leader in plasma-derived medicines, reported a strong third quarter in 2024, with a 12.1% growth in Biopharma driving total revenues to 1.793 billion euros. The company achieved a 26.7% increase in adjusted EBITDA due to a better product mix and reduced plasma costs, while net profit reached 88 million euros despite non-recurring expenses. Grifols remains focused on deleveraging and generating free cash flow, reaffirming its robust financial outlook for the year.
For further insights into ES:GRF stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ZGD, HGGG: 2 Gold ETFs with More than 20% Expected Returns, According to Analysts
- Immunic Reports Q3 Earnings and Provides Corporate Update
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
